The migraine drug Aimovig comes on a blue prescription and will become cheaper after price negotiations between Hospital Procurement (Sykehusinnkjøp) and drug manufacturer Novartis
“I am very pleased that Norwegian patients with chronic migraine will have access to Aimovig on a blue prescription from December 9th. The price negotiations have meant that patients receive the medicine faster than if it were managed by Parliament (Stortinget). This shows that price negotiation is an important tool for achieving an acceptable price for new medicines,” says Minister of Health Bent Høie (Høyre/Conservative Party).
In order for a patient to receive the medicine on a blue prescription, individual support must be sought through Helfo. The application must come from a specialist in neurology, a doctor at a neurological department or an outpatient clinic at a hospital.
Patients must have tried at least three other preventive drugs before applying for Aimovig treatment.
All patients who meet the criteria for migraine medicine will, despite the eight-week processing time, be reimbursed the expenses incurred as of December 9th.
© NTB Scanpix / #Norway Today